Sunday, August 16, 2020 4:17:29 PM
Unique, favorable molecular architectures.
The Anavex sigma-1 receptor agonists, Anavex 2-73 (blarcamesine) and Anavex 3-71, are shaped like none of the other, less favorable sigma-1 receptor agonists (those mentioned in the article).
Understand, small proteins (such as the sigma-1 receptor) are flexible, malleable; able to be re-shaped or re-configured by the interplay of the multiple adhesive forces between the protein and any attached ligands, other properly-fitting molecules (such as those of Anavex).
In cellular biochemistry, shape is everything. When a modulating molecule such as the sigma-1 receptor is bent out of its properly-functioning shape (which apparently can happen with age or genetic factors), chemical reactions controlled or modulated by the molecule don't happen as often or as thoroughly. In the case of neurons with poorly-shaped sigma-1 receptor proteins, various pathologies result (including Alzheimer's, Parkinson's disease dementia, and Rett syndrome). The Anavex molecules bind to the sigma-1 receptor proteins, and thereby re-shape them to full chemical functionality, allowing them to subsequently modulate a variety of ensuing chemical reactions and processes, all of which restore chemical homeostatic processes within the neuron. The neuron is reverted to a more youthful, more fully functional status.
It's the shape. Simply, the Anavex molecules shape things up inside aging or genetically mal-affected neurons.
And the phenomenal biochemistry comes from?
The Anavex sigma-1 receptor agonists, Anavex 2-73 (blarcamesine) and Anavex 3-71, are shaped like none of the other, less favorable sigma-1 receptor agonists (those mentioned in the article).
Understand, small proteins (such as the sigma-1 receptor) are flexible, malleable; able to be re-shaped or re-configured by the interplay of the multiple adhesive forces between the protein and any attached ligands, other properly-fitting molecules (such as those of Anavex).
In cellular biochemistry, shape is everything. When a modulating molecule such as the sigma-1 receptor is bent out of its properly-functioning shape (which apparently can happen with age or genetic factors), chemical reactions controlled or modulated by the molecule don't happen as often or as thoroughly. In the case of neurons with poorly-shaped sigma-1 receptor proteins, various pathologies result (including Alzheimer's, Parkinson's disease dementia, and Rett syndrome). The Anavex molecules bind to the sigma-1 receptor proteins, and thereby re-shape them to full chemical functionality, allowing them to subsequently modulate a variety of ensuing chemical reactions and processes, all of which restore chemical homeostatic processes within the neuron. The neuron is reverted to a more youthful, more fully functional status.
It's the shape. Simply, the Anavex molecules shape things up inside aging or genetically mal-affected neurons.
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
